This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
- Investigator
- Cesar A Trillo-Alvarez
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
Research at a glance
Top areas of exploration
- Acute Lung Injury , 2 publications
- Respiratory Distress Syndrome , 2 publications
- Critical Illness , 2 publications
- Anti-Bacterial Agents , 1 publications
Research activity
Active clinical trials
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to鈥�
- Investigator
- Cesar A Trillo-Alvarez
- Status
- Accepting Candidates
- Ages
- 18 Years - 64 Years
- Sexes
- All
My publications
Filter publications
11 publications
2024
A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia.
Therapeutic drug monitoring
鈥�2021
Ustekinumab associated chronic eosinophilic pneumonia.
The Journal of asthma : official journal of the Association for the Care of Asthma
鈥�2019
Multidisciplinary Care for Cystic Fibrosis Liver Disease: Where Does the Adult Hepatologist Fit In?
Clinical liver disease
鈥�2018
Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease.
World journal of hepatology
鈥�2011
Acute lung injury prediction score: derivation and validation in a population-based sample.
The European respiratory journal
鈥�